

20
09



		Q1-3/2009	Q1-3/2008	Change
Sales	Million EUR	77.8	51.5	51%
Return on revenue before tax (operational)	%	13%	11%	15%
EBITDA	Million EUR	16.1	21.1	not comparable
EBIT	Million EUR	10.8	14.9	not comparable
EBT	Million EUR	9.8	14.3	not comparable
EBT (operational)	Million EUR	9.8	5.6	74%
Net income/loss before other shareholders' interests	Million EUR	8.0	9.3	not comparable
Profit	Million EUR	5.3	11.0	not comparable
Earnings per share (basic)	EUR	1.44	3.51	not comparable
Earnings per share (operational, basic)	EUR	1.44	0.94	54%
Operational cash flow	Million EUR	12.0	0.8	>100%
Depreciation and amortization on non-current assets	Million EUR	5.3	6.1	-14%
Staff as of September 30	Persons	519	419	24%

Cover page:

The awarding of the EANM Eckert & Ziegler Abstract Award to five aspiring young scientists on the occasion of the annual congress of the European Association of Nuclear Medicine (EANM) in Barcelona.

The 100th MultiSource® Co-60 HDR (High Dose Rate) cancer irradiation device was supplied to Thailand.

Disclaimer:

The official version of this quarterly report is in German. The English translation is provided as a convenience to our shareholders. While we strive to provide an accurate and readable version of our quarterly report in English, the technical nature of a quarterly report often yields awkward phrases and sentences. We understand this can cause confusion. So, please always refer to the German quarterly report for the authoritative version.

Business development of the Eckert & Ziegler Group

Revenue growth

In the first nine months of 2009, the Eckert & Ziegler Group set new records with sales of EUR 78 million and Group profits of EUR 5.3 million, thus far exceeding the existing operative records. Compared with last year's period, sales increased by EUR 26 million, or 51%. Compared with the same nine-month period in the previous year, the profit after tax and minority interests increased by EUR 2.4 million, or 79%, if the special effect resulting from the IBt consolidation in that period is excluded. The profit per share for the three quarters of 2009 taken together equals EUR 1.44.

This enormous success is based on the very positive figures from all three operative segments. Sales in the therapy segment have increased by 26%, or approx. EUR 5 million. The drivers of growth were above all the tumor irradiation equipment, sales of which increased by 55%, or about EUR 2 million, due in particular to increased sales to eastern Europe. The first sales from the Russian project amounting to about EUR 3 million were already included in the second quarter of 2009. International Brachytherapy s.a. (IBt), an associated company of Eckert & Ziegler, had in the first half of the year set up a joint venture with a Russian state fund corporation to manufacture prostate cancer implants in Russia, and had begun supplying plant and equipment.

In the Nuclear Medicine and Industry segment, sales have almost doubled from EUR 22.2 million to EUR 39.6 million. This resulted from the combined effects of including the Nuclitec sales, the increased sales of robust drill hole sources, and a USD exchange rate improvement of 6%.

Despite the loss of sales in Italy, the Radiopharmaceuticals segment grew by 38%. The two main product categories, Modular-Lab and diagnostics for positron emission tomography (PET), continued their uninterrupted growth trend from the previous quarters. Added to this were Nuclitec's aurigamedical sales.

Earnings position

The Therapy segment is turning into an earnings machine. Last year's restructuring costs had a detrimental effect, resulting in only a very modest profit. Now, however, this highly profitable operational business is making a decisive contribution to increasing Group profits. In addition, the start-up of the Russian project already provided additional profits in the second quarter.

The Nuclear Medicine and Industry segment was still the main sources of revenues, just as in previous periods. Sales have increased by 79%. Approximately a third of that, i.e. 25% growth, can be seen in profits after tax and minority interests, which have increased by EUR 0.9 million compared with the same period last year and which now stand at EUR 4.3 million. The results also show that Nuclitec had been integrated successfully and was likewise turning in profits.


The Radiopharmaceuticals segment continues to make a profit despite high launch costs for introducing new products. Gains from the deconsolidation of the Italian stake further increased profits.

The Other segment includes the costs of the holding company which was faced with high lawyer fees in connection with the IBt lawsuit during the current financial year.


The brief segment statistics on the following page (in thousands of euros) illustrate the sources of turnover and profit.

Liquidity

The superlative key figure of the first nine months of 2009 is the operative cash flow of EUR 12.0 million, which also sets a new record. Although earnings for the period declined compared to the previous quarters, the operating cash flow continued to increase, and amounts to EUR 5.5 million in the third quarter of 2009 alone.



Legend:
█ Q1-2008
█ Q1-2009



Legend:
█ Q1-2008
█ Q1-2009

		Therapy (IBt)	Nuclear Medicine and Industry	Radio-pharmaceuticals	Other	Total
External turnover						
	Q1-3/2008	18,916	22,164	10,374	39,631	51,454
	Q1-3/2009					77,827
Profit after tax	Q1-3/2008	477	3,672	-634	35	3,550
	Q1-3/2009		4,038	4,492	148	8,018
Net profit ratio in %	Q1-3/2008	3%	17%	-6%		7%
	Q1-3/2009		17%	11%	1%	10%
Turnover growth	absolute	+4,961	+17,467	+3,945		+26,373
	in %	+26%	+79%	+38%		+51%
Profit growth	absolute	+3,561	+820	+782		+4,468
	in %	+747%	+22%			+126%

As each segment has different minority interests, profit after tax was used as a reference. The figures for 2008 have been adjusted to compensate for the special effects of the IBt consolidation.

A comparison with the first three quarters of 2008 is not very informative because in the comparison period the non-cash effects were dominant, but only a slight operational cash inflow was posted. This is in stark contrast to 2009, where the cash flow from business activities is above the profit figure for the period, which itself is very high.

The main reason for this success lies in the fact that, despite the huge increase in sales, receivables were able to be reduced once the payment of the first Russian project turnover, which was only made in October, is disregarded. Inventories were also able to be reduced. Only the reduction of accounts payable led to liquidity outflows.

The investments of EUR 8.2 million for the Nuclitec shares, less the cash reserves, and in property, plant and equipment were largely financed by the capital increase and by taking out loans totaling EUR 5.1 million. This means that the cash gain from the operative capital flow of EUR 12.0 million was reduced by a total of EUR 3.1 million from investments and financing. The dividend payment of EUR 1.1 million is also to be deducted, as well as the change due to the purchase/issue of EUR 0.2 million own shares. Overall, the cash reserves increased by EUR 7.5 million to EUR 14.8 million on September 30, 2009.

Research and development

Work in the Therapy segment concentrated on the development of a complete plant for the production of prostate cancer implants for Russia. The specification was finalized for most of the plant's modules, and the actual development phase was begun.

The range of accessories for the cancer irradiation devices was expanded with improved applicators for use in treating breast cancer and new Fletcher applicators for use in gynecology.

In the Radiopharmaceuticals and the Nuclear Medicine and Industry segments, the focus was on the ongoing further development of existing product lines.

Staff

As of September 30, 2009, the Eckert & Ziegler Group had 348 employees in Germany, and a total of 519 employees worldwide. Compared with the end of 2008, the number of staff increased by 110 (December 31, 2008: 409). This increase is mainly due to the inclusion of the Nuclitec companies.

Outlook

The sales target for the 2009 financial year is EUR 100 million. The Executive Board is maintaining its profits forecast of EUR 6.6 million (EUR 1.80 per share), although this figure does not include any special effects of the whole or partial reversal of provisions in connection with the legal dispute regarding IBt (EUR 7.1 million).

3/2009

Milestones

- The 628,633 shares from the increase in capital decided upon in January 2009 were authorized for trading in the regulated market (Prime Standard) of the Frankfurt stock exchange.
- International Brachytherapy S.A. (IBt), an associated company of Eckert & Ziegler AG, has supplied the 100th MultiSource® Co-60 HDR (High Dose Rate) cancer irradiation device. The Vajira Hospital in Bangkok, Thailand will use it principally to treat tumors of the uterus, breast and esophagus.
- Eckert & Ziegler awarded the EANM Eckert & Ziegler Abstract Award to five nuclear medicine researchers for their outstanding scientific work. The award ceremony took place at the annual congress of the European Association of Nuclear Medicine in Barcelona.



Photos (from top to bottom):

MultiSource® applicator for brachytherapy treatment of gynecologic tumors.

The Vajira Hospital in Bangkok will use the MultiSource® cancer irradiation device principally to treat tumors of the uterus, breast and esophagus.

This year's EANM Eckert & Ziegler Abstract Award was awarded to nuclear medicine researchers for their outstanding work in the fields of cancer diagnostics and therapies.



	Quarterly Report III/2009 07-09/2009	Quarterly Report III/2008 07-09/2008	9-monthly Report 01-09/2009	9-monthly Report 01-09/2008
	TEUR	TEUR	TEUR	TEUR
Net sales	25,474	18,640	77,827	51,454
Cost of sales	-12,710	-10,835	-37,454	-29,305
Gross profit on sales	12,764	7,805	40,373	22,149
Selling expenses	-4,075	-3,532	-14,023	-9,976
General and administrative expenses	-4,975	-3,446	-14,484	-9,871
Research and non-capitalized development expenses	-782	-1,337	-1,725	-3,409
Other operating income	205	1,235	878	2,631
Other operating expenses	-29	-643	-256	-729
Profit from operations	3,108	82	10,763	795
Other financial items	-137	352	56	14,142
Earnings before interest and taxes (EBIT)	2,971	434	10,819	14,937
Interest received	10	55	40	97
Interest paid	-345	-198	-1,068	-702
Profit before tax	2,636	291	9,791	14,332
Income tax expense	-429	-824	-1,773	-5,003
Profit from continuing operations	2,207	-533	8,018	9,329
Profit from discontinued operations, net	-	-	97	-
Net income	2,207	-533	8,115	9,329
Profit/loss attributable to minority interests	-853	2,184	-2,796	1,698
Dividend to shareholders of Eckert & Ziegler AG	1,354	1,651	5,319	11,027
Earnings per share				
Basic	0.36	0.53	1.44	3.51
Diluted	0.36	0.52	1.44	3.49
Average number of shares in circulation (basic)	3,751	3,143	3,686	3,143
Average number of shares in circulation (diluted)	3,771	3,161	3,700	3,161

	9-monthly Report 01-09/2009 TEUR	9-monthly Report 01-09/2008 TEUR
Cash flows from operating activities:		
Profit for the period	8,116	9,329
Adjustments for:		
Depreciation and amortization	5,268	6,132
Proceeds from grants less release of deferred income from grants	45	-403
Deferred tax	-410	2,655
Unrealized foreign currency gains/losses	-51	-841
Long-term provisions, other non-current liabilities	394	-1,002
Gains/losses on the sale of consolidated companies	-	-13,985
Gains/losses on the disposal of non-current assets	49	-
Gains/losses on the sale of securities	-	-77
Other	-54	33
Changes in current assets and liabilities:		
Receivables	-487	-456
Inventories	613	-535
Prepaid expenses, other current assets	-176	-287
Trade accounts payable and accounts payable to related parties	-1,680	-562
Income tax liabilities	-1,174	486
Other liabilities	1,525	351
Cash inflows generated from operating activities	11,978	838
Cash flows from investment activities:		
Purchase/sale of non-current assets	-4,007	-5,714
Acquisition of consolidated companies	-4,320	2,179
Purchase/sale of shareholdings	28	40
Purchase/sale of securities	101	690
Cash inflows/outflows from investment activities	-8,198	-2,805
Cash flows from financing activities:		
Dividends paid	-1,132	-786
Cash inflow from capital increase	2,959	-
Change in long-term borrowings	5,427	3,758
Change in short-term borrowings	-3,295	712
Acquisition of own shares	-431	-
Own shares used for share options or acquisitions	218	-
Cash inflows/outflows from financing activities	3,746	3,684
Effect of exchange rates on cash and cash equivalents	-66	54
Increase (reduction) in cash and cash equivalents	7,460	1,771
Cash and cash equivalents at beginning of period	7,311	4,375
Cash and cash equivalents at end of period	14,771	6,146

	Sep. 30, 2009 TEUR	Dec. 31, 2008 TEUR
ASSETS		
Non-current assets		
Intangible assets	46,269	38,726
Property, plant and equipment	27,422	23,807
Equity investments	-	278
Deferred tax	2,001	1,210
Other assets	1,027	1,118
Total non-current assets	76,719	65,139
Current assets		
Cash and cash equivalents	14,771	7,311
Securities	236	332
Trade accounts receivable	18,388	13,985
Inventories	12,532	8,555
Other assets	2,984	2,464
Assets held for disposal	-	1,012
Total current assets	48,911	33,659
Total assets	125,630	98,798
EQUITY AND LIABILITIES		
Shareholders' equity		
Subscribed capital	3,910	3,250
Capital reserves	33,256	30,316
Retained earnings	14,702	10,946
Other reserves	-3,736	-3,297
Own shares	-787	-359
Equity due to the shareholders of Eckert & Ziegler AG	47,345	40,856
Minority interests	4,264	1,964
Total shareholders' equity	51,609	42,820
Non-current liabilities		
Long-term borrowings and finance lease obligations	17,324	10,761
Deferred income from grants and other deferred income	1,458	1,416
Deferred tax	1,660	1,147
Retirement benefit obligations	5,421	420
Other provisions	23,815	15,969
Other liabilities	584	529
Total non-current liabilities	50,262	30,242
Current liabilities		
Short-term borrowings and finance lease obligations	3,527	7,751
Trade accounts payable	3,823	4,286
Advance payments received	2,202	1,002
Deferred income from grants and other deferred income	374	371
Current tax payable	486	916
Other liabilities	13,347	10,285
Liabilities held for disposal	-	1,125
Total current liabilities	23,759	25,736
Total equity and liabilities	125,630	98,798

	Cumulative other equity items						Group share-holders'		
	Subscribed capital						Equity attributable to shareholders	Minority shares	
	Shares	Nominal value	Capital reserve	Retained earnings	Unrealized gains/losses on securities	Foreign currency exchange differences	TEUR	TEUR	TEUR
		TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
Balance January 1, 2008	3,250,000	3,250	29,750	7,230	42	-3,776	-359	36,137	354
Foreign currency translation differences						472		472	472
Unrealized gains/losses on securities at balance sheet date (after tax of EUR 3 thousand)					7			7	7
Reversal of unrealized gains/losses on securities at previous balance sheet date					-42			-42	-42
Total of expenditures and income directly entered in equity	0	0	0	0	-35	472	0	437	0
Profit of the year				4,502				4,502	-1,465
Total income for the period	0	0	0	4,502	-35	472	0	4,939	3,037
Dividends paid				-786				-786	-104
Purchase of minority interests								0	3,179
Provisions offset by own shares				566				566	566
Balance December 31, 2008	3,250,000	3,250	30,316	10,946	7	-3,304	-359	40,856	1,964
									42,820

	Cumulative other equity items						Group share-holders'		
	Subscribed capital						Equity attributable to shareholders	Minority shares	
	Shares	Nominal value	Capital reserve	Retained earnings	Unrealized gains/losses on securities	Foreign currency exchange differences	TEUR	TEUR	TEUR
		TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
Balance January 1, 2009	3,250,000	3,250	30,316	10,946	7	-3,304	-359	40,856	1,964
Foreign currency translation differences						-443		443	443
Unrealized gains/losses on securities at balance sheet date (after tax of EUR 5 thousand)					11			11	11
Reversal of unrealized gains/losses on securities at previous balance sheet date					-7			-7	-7
Total of expenditures and income directly entered in equity	0	0	0	0	4	-443	0	-439	0
Profit of the year				5,320				5,320	2,796
Total income for the period	0	0	0	5,320	4	-443	0	4,881	8,116
Dividends paid				-1,132				-1,132	0
Purchase and sale of minority interests								0	-496
Application of own shares for acquisitions and to service share options	31,650	32	177			4	213		213
Acquisition or own shares			432	-432		-432	-432		-432
Capital increase	628,633	629	2,330					2,959	2,959
Balance September 30, 2009	3,910,283	3,910	33,256	14,702	11	-3,747	-787	47,345	4,264
									51,609

	Nuclear Medicine and Industry		Therapy		Radio-pharmaceuticals		Other		Elimination		Total	
	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008
	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
Sales to external customers	39,631	22,164	23,877	18,916	14,319	10,374	0	0	0	0	77,827	51,454
Sales to other segments	392	191	281	1,545	29	60	762	1,068	-1,464	-2,864	0	0
Total segmental sales	40,023	22,355	24,158	20,461	14,348	10,434	762	1,068	-1,464	-2,864	77,827	51,454
Segment profit before interest and profit taxes (EBIT)	7,022	5,730	4,485	-3,877	872	-236	-1,549	13,329	-11	-9	10,819	14,937
Interest yield and paid	-416	-312	-464	-305	-749	-726	590	729	11	9	-1,028	-605
Income tax expense	-2,114	-1,746	17	-352	25	-1,640	299	-1,265			-1,773	-5,003
Profit before minority interests	4,492	3,672	4,038	-4,534	148	-2,602	-660	12,793			8,018	9,329
Special effects before minority interests	0	0	0	-5,011	0	-1,968	0	12,758			0	5,779
Profit before minority interests without special effects	4,492	3,672	4,038	477	148	-634	-660	35			8,018	3,550

	Nuclear Medicine and Industry		Therapy		Radio-pharmaceuticals		Other		Total	
	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008	01-09 2009	01-09 2008
	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
Segmental assets	60,593	31,152	45,728	43,903	18,240	16,577	76,997	51,891	201,558	143,523
Elimination of inter-segmental shares, equity investments and receivables									-77,928	-58,521
Deferred tax assets									2,001	8,961
Consolidated total assets									125,631	93,963
Segmental liabilities	-32,924	-13,597	-20,987	-17,308	-20,803	-19,078	-26,743	-5,662	-101,457	-55,645
Elimination of inter-segmental liabilities									29,095	17,282
Deferred tax liabilities									-1,660	-2,134
Consolidated liabilities									-74,022	-40,497
Investments	1,052	3,679	1,277	1,263	1,675	750	3	22	4,007	5,714
Depreciations (without non-scheduled depreciations)	-1,695	-743	-1,956	-2,333	-1,469	-1,159	-148	-143	-5,268	-4,378
Non cash income/expenses	-62	259	113	1,760	-237	-1,735	213	13,336	27	13,620

Sales by geographic areas	Jan.– Sep. 2009		Jan.– Sep. 2008	
	Million EUR	%	Million EUR	%
Europe	48.3	62	31.3	60
North America	21.0	27	15.2	30
Asia/Pacific	7.8	10	4.0	8
Other	0.7	1	1.0	2
Total	77.8	100	51.5	100

1. General information

These unaudited interim consolidated financial statements as of September 30, 2009 comprise the financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG and its subsidiaries (also referred to hereinafter as "Eckert & Ziegler AG").

2. Accounting and valuation methods

The consolidated financial statements (interim financial statements) of Eckert & Ziegler AG as of September 30, 2009, have been prepared, like the annual financial statements for 2008, in accordance with the International Financial Reporting Standards (IFRS). All of the standards of the London-based International Accounting Standards Board (IASB) which were applicable in the EU on the balance sheet date, as well as the relevant interpretations of the International Financial Reporting Interpretations Committee (IFRIC) and the Standing Interpretations Committee (SIC), have been observed. The accounting and valuation methods described in the appendix to the annual financial statements for 2008 have been applied unchanged. For the preparation of the consolidated financial statements in compliance with the IFRS, it is necessary for estimates and assumptions to be made that impact on the amount and disclosure of recognized asset values and liabilities, income and expenditures. The actual values may differ from the estimates. Significant assumptions and estimates are made concerning useful lives, earnings attainable from goodwill and non-current assets, the realizability of receivables, and the recognition and measurement of provisions. This interim report contains all of the necessary information and adjustments required to produce a picture which reflects the actual circumstances in respect of the assets, financial situation and earnings position of Eckert & Ziegler AG at the time the interim report was produced. The earnings achieved during the course of the current fiscal year do not necessarily allow conclusions to be drawn about the development of future earnings.

3. Companies included in the consolidation

In the consolidated financial statements of Eckert & Ziegler AG, all companies are included where Eckert & Ziegler AG, either indirectly or directly, is able to determine the financial and business policies (control concept).

Company acquisitions and disposals

On January 23, 2009, Eckert & Ziegler AG exercised the purchase option it obtained in December 2008 and purchased all the shares in nuclitec GmbH in Braunschweig, its American subsidiary nuclitec Inc., and the French sister company nuclitec s.a.r.l. The purchase price for the shares amounted to EUR 6,859,000. The ancillary purchase costs amount to EUR 35,000. At the time of publishing this interim financial report, the data gathering required for identifying and evaluating the asset values, debts and potential debts was not yet complete. For this reason, the initial accounting for the acquisition of the company could only be carried out provisionally in accordance with IAS 3.62 at the end of the interim financial statement period.

The acquisition of nuclitec GmbH and its American subsidiary, nuclitec Inc., will be recorded on the balance sheet in this interim financial statement with the following provisional figures:

	Book values TEUR	Fair value* TEUR
Non-current assets	5,636	9,709
Current assets	11,329	11,329
Non-current debts	-14,080	-15,366
Current debts	-4,076	-4,076
Net assets	-1,191	1,596
Acquisition costs		6,158
Goodwill		4,562

* The calculation of the fair values of the assets and debts is not yet completed. Therefore provisional values have been used in accordance with IFRS 3.62.

The acquisition of nuclitec s.a.r.l. will be recorded on the balance sheet in this interim financial statement with the following provisional figures:

	Book values TEUR	Fair value* TEUR
Non-current assets	2	2
Current assets	1,057	1,057
Non-current debts	-398	-398
Current debts	-287	-287
Net assets	374	374
Acquisition costs		736
Goodwill		362

* The calculation of the fair values of the assets and debts is not yet completed. Therefore provisional values have been used in accordance with IFRS 3.62.

In March 2009, Eckert & Ziegler AG sold its Milan subsidiary Eckert & Ziegler f-con Pharma Italia s.r.l. (FCI) to the Italian company A.C.O.M. – Advanced Center Oncology Macerata SPA. The deconsolidation of FCI resulted in non-cash revenue of EUR 97,000 in the present interim financial statement.

4. Limited comparability of group financial statements with the previous year

In 2008, Eckert & Ziegler AG invested the Therapy segment business in IBt S.A., Seneffe (Belgium) and, in return for this, received 38.5% of the ordinary shares (which equates to 29.9% of the voting shares) in IBt S.A. arising from a capital increase and the loan-related claims. In June 2008, Eckert & Ziegler BEBIG GmbH took over the implants manufacturer Isotron

Isotopentechnik GmbH. In January 2009 the shares of the companies nuclitec GmbH, nuclitec s.a.r.l. and nuclitec Inc. were purchased. In the first quarter of 2009 the shares in Eckert & Ziegler f-con Pharma Italia s.r.l. were sold.

Compared with the first nine months of 2008, this has impacted substantially on the financial situation and earnings position of the Group, which means that it is difficult to compare the Group report with the previous year's report.

5. Currency translation

The financial statements for the companies outside the European Monetary Union are translated based on the concept of functional currency. The following exchange rates were used for the currency translation: See table below

6. Portfolio of own shares

As of September 30, 2009, Eckert & Ziegler AG held 140,916 own shares. This equates to a share of 3.6% of the Company's nominal capital.

7. Substantial transactions with affiliated persons

In respect of the substantial transactions with affiliated persons, we refer to the publications made in the consolidated financial statements dated December 31, 2008.

Country	Currency	Exchange rate on Sep. 30, 2009	Exchange rate on Dec. 31, 2008	Average rate: Jan. 1 - Sep. 30, 2009	Average rate: Jan. 1 - Sep. 30, 2008
USA	USD	1.4592	1.4097	1.3606	1.4398
Czech Republic	CZK	25.2204	26.6426	26.9679	24.6554
Great Britain	GBP	0.9166	0.974	0.8872	n.a.
Sweden	SEK	10.2247	10.9861	10.7215	n.a.

8. Events of special significance

Eckert & Ziegler Strahlen- und Medizintechnik AG has been commissioned to produce an innovative cancer medication for the American drug developer Molecular Insight Pharmaceuticals (NASDAQ: MIPI) based in Cambridge, MA. Under the terms of the agreement signed on October 21, 2009, Eckert & Ziegler will set up a new production plant for this purpose over the next few years at its Braunschweig location with financial support from MIPI. The compound Onalta® is a novel radiotherapeutic product candidate under development for the treatment of neuroendocrine tumors. The production plants will be used both for the manufacture of test batches for clinical development and, later, for the manufacture of the approved radiopharmaceuticals.

Berlin, November 3, 2009

Dr. Andreas Eckert
Chief Executive Officer

Dr. Edgar Löffler
Executive Board Member

Dr. André Heß
Executive Board Member

Financial Calendar

November 03, 2009

Quarterly Report III/2009

November 11, 2009

German Equity Forum in Frankfurt

March 30, 2010

Annual Report 2009

March 30, 2010

Balance Press Conference in Berlin

May 04, 2010

Quarterly Report I/2010

May 20, 2010

Annual General Meeting in Berlin

August 03, 2010

Quarterly Report II/2010

November 02, 2010

Quarterly Report III/2010

November 2010

German Equity Forum in Frankfurt

Contact

Eckert & Ziegler
Strahlen- und Medizintechnik AG

Karolin Riehle
Investor Relations

Robert-Rössle-Str. 10
13125 Berlin
www.ezag.com

Telephone +49 (0) 30 94 10 84 - 0
Telefax +49 (0) 30 94 10 84 - 112
E-Mail karolin.riehle@ezag.de

ISIN	DE000565970
ISIN	DE000A0L1L69
WKN	565970